alitretinoin has been researched along with Nerve-Degeneration* in 2 studies
2 other study(ies) available for alitretinoin and Nerve-Degeneration
Article | Year |
---|---|
9-Cis retinoic acid protects against methamphetamine-induced neurotoxicity in nigrostriatal dopamine neurons.
Methamphetamine (MA) is a drug of abuse as well as a dopaminergic neurotoxin. 9-Cis retinoic acid (9cRA), a biologically active derivative of vitamin A, has protective effects against damage caused by H(2)O(2) and oxygen-glucose deprivation in vitro as well as infarction and terminal deoxynucleotidyl transferase-mediated dNTP nick-end labeling (TUNEL) labeling in ischemic brain. The purpose of this study was to examine if there was a protective role for 9cRA against MA toxicity in nigrostriatal dopaminergic neurons. Primary dopaminergic neurons, prepared from rat embryonic ventral mesencephalic tissue, were treated with MA. High doses of MA decreased tyrosine hydroxylase (TH) immunoreactivity while increasing TUNEL labeling. These toxicities were significantly reduced by 9cRA. 9cRA also inhibited the export of Nur77 from nucleus to cytosol, a response that activates apoptosis. The interaction of 9cRA and MA in vivo was next examined in adult rats. 9cRA was delivered intracerebroventricularly; MA was given (5 mg/kg, 4×) one day later. Locomotor behavior was measured 2 days after surgery for a period of 48 h. High doses of MA significantly reduced locomotor activity and TH immunoreactivity in striatum. Administration of 9cRA antagonized these changes. Previous studies have shown that 9cRA can induce bone morphogenetic protein-7 (BMP7) expression and that administration of BMP7 attenuates MA toxicity. We demonstrated that MA treatment significantly reduced BMP7 mRNA expression in nigra. Noggin (a BMP antagonist) antagonized 9cRA-induced behavioral recovery and 9cRA-induced normalization of striatal TH levels. Our data suggest that 9cRA has a protective effect against MA-mediated neurodegeneration in dopaminergic neurons via upregulation of BMP. Topics: Alitretinoin; Animals; Bone Morphogenetic Protein 7; Carrier Proteins; Cells, Cultured; Corpus Striatum; Dopaminergic Neurons; Male; Methamphetamine; Motor Activity; Nerve Degeneration; Neuroprotective Agents; Neurotoxicity Syndromes; Nuclear Receptor Subfamily 4, Group A, Member 1; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Tretinoin; Tyrosine 3-Monooxygenase | 2014 |
Retinoic acid isomers protect hippocampal neurons from amyloid-beta induced neurodegeneration.
Attenuating amyloid-beta mediated neurodegeneration is of major therapeutic consideration in the potential treatment of Alzheimer disease. Previously, we found that a high dietary consumption of retinoic acid was associated with a reduced incidence of Alzheimer disease. Therefore, in this study, we investigated whether amyloid-beta mediated cell death in primary hippocampal neurons could be prevented by retinoic acid isomers. Our results suggest that retinoic acid isomers, including all-trans retinoic acid, 9-cis retinoic acid, and 13-cis retinoic acid, may play an important role in protecting neurons from amyloid-beta -induced cell death. Retinoic acid may therefore afford a novel therapeutic mechanism for the treatment and prevention of Alzheimer disease. Topics: Alitretinoin; Amyloid beta-Peptides; Animals; Animals, Newborn; Cell Count; Cell Death; Dose-Response Relationship, Drug; Drug Interactions; Hippocampus; Isotretinoin; Nerve Degeneration; Neurons; Peptide Fragments; Protein Isoforms; Rats; Tretinoin | 2005 |